Abstract:Background: Mitochondrial fission regulator 2 (MTFR2) which can promote mitochondrial fission, has recently been reported to be involved in tumorigenesis. However, little is known about its expression levels and function in gastric cancer (GC). This study aims to clarify the role of MTFR2 in GC. Methods:We firstly determined the expression level and prognostic value of MTFR2 in GC by integrated bioinformatics (Oncomine, GEPIA, Kaplan-Meier Plotter database) and experimental approaches (RT-qPCR, western blot, immunohistochemistry). After constructing stable down-regulated GC cells, the biological functions of MTFR2 in vitro and in vivo were studied through cell clone formation, wound healing, transwell and tumor formation experiments.To understand the reason for the high expression of MTFR2 in GC, copy number alternation, promoter methylation and mutation of MTFR2 were detected by UALCAN and cBioPortal. TargetScanHuman and PROMO databases were also used to explore the miRNAs and transcription factors of MTFR2, and the regulatory network was visualized by Cytoscape. LinkedOmics was used to detect the co-expression profile, and then these co-expressed genes were used for gene oncology function and pathway enrichment analysis to deepen the understanding of MTFR2 mechanism. The protein interaction network of MTFR2 was constructed by the GeneMANIA platform. Docking study of the binding mode was conducted by H DOCK webserver, and PYMOL is used for visualization, and analysis. TIMER database was used to explore the correlation between MTFR2 expression level and immune cells infiltration and gene markers of tumor infiltrating immune cells. Results: We demonstrated that MTFR2 was up-regulated in GC, and its overexpression led to poorer prognosis. MTFR2 downregulation inhibited the proliferation, migration, and invasion of GC cells in vitro and in vivo. By bioinformatics analysis, we identified the possible factors in MTFR2 overexpression. Moreover, function and pathway enrichment analyses found that MTFR2 was involved in chromosome segregation, catalytic activity, cell cycle, and ribonucleic acid transport. A MTFR2-protein interaction network revealed a potential direct protein interaction between MTFR2 and protein kinase adenosine-monophosphate-activated catalytic subunit alpha 1 (PRKAA1), and their potential binding site was predicted in a molecular docking model. In addition, we also found that MTFR2 may be correlated with immune infiltration in GC. Conclusions: Our study has effectively revealed the expression, prognostic value, potential functional networks, protein interactions and immune infiltration of MTFR2 in GC. Altogether, our data identify the possible underlying mechanisms of MTFR2 and suggest that MTFR2 may be a prognostic biomarker and therapeutic target in GC.

Upregulated expression of <i>MTFR2</i> as a novel biomarker predicts poor prognosis in hepatocellular carcinoma by bioinformatics analysis

Expression of Mta2 and Ki-67 in Hepatocellular Carcinoma and Their Correlation with Prognosis

Over-expression of RRM2 predicts adverse prognosis correlated with immune infiltrates: A potential biomarker for hepatocellular carcinoma

MTFR2 shapes a barrier of immune microenvironment in hepatocellular carcinoma

Comprehensive Analysis of the Prognosis for Chemokine-Like Factor MARVEL Transmembrane Domain-Containing Family in Hepatocellular Carcinoma

The Role of the Mitochondrial Ribosomal Protein Family in Detecting Hepatocellular Carcinoma and Predicting Prognosis, Immune Features, and Drug Sensitivity.

MTFR2, A Potential Biomarker for Prognosis and Immune Infiltrates, Promotes Progression of Gastric Cancer Based on Bioinformatics Analysis and Experiments

C18ORF54 promotes immune infiltration and poor prognosis as a potential biomarker for hepatocellular carcinoma

Expression Profile Reveals Novel Prognostic Biomarkers in Hepatocellular Carcinoma.

Prognostic Value and Potential Mechanism of MTFR2 in Lung Adenocarcinoma

Integrated single-cell and bulk RNA sequencing analysis revealing the role of FCGR2A on prognosis and immune infiltration of hepatocellular carcinoma

Upregulated mH2A1 serves as an unfavorable prognostic indicator and promotes the progress of hepatocellular carcinoma (HCC)

Identifying potential prognosis markers in hepatocellular carcinoma via integrated bioinformatics analysis and biological experiments

A novel mitochondrial unfolded protein response-related risk signature to predict prognosis, immunotherapy and sorafenib sensitivity in hepatocellular carcinoma

Upregulation of Microfibrillar-Associated Protein 2 is Closely Associated with Tumor Angiogenesis and Poor Prognosis in Hepatocellular Carcinoma.

High Mir-454-3p Expression Predicts Poor Prognosis in Hepatocellular Carcinoma

Identification of MTCH1 as a novel prognostic indicator and therapeutic target in hepatocellular carcinoma

High Expression of RRM1 Mediated by Ncrnas Correlates with Poor Prognosis and Tumor Immune Infiltration of Hepatocellular Carcinoma

High expression of RRM2 mediated by non-coding RNAs correlates with poor prognosis and tumor immune infiltration of hepatocellular carcinoma

Five metastasis-related mRNAs signature predicting the survival of patients with liver hepatocellular carcinoma

Prognostic significance of pyrimidine metabolism-related genes as risk biomarkers in hepatocellular carcinoma